Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications

Glucotrack's subsidiary Lōkahi Therapeutics launched Qare, a health platform for comparing medication experiences, starting with GLP-1 drugs. The app matches users by profile and medication, generating real-world data. Lōkahi aims to expand Qare to other therapeutic categories and believes it may offer long-term value to patients and manufacturers.

Original reporting
Published Oct 15, 2026, 4:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 6:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications — source image
Decision brief

The 30-second read

$GCTKNeutralLow
01

Why it matters

The platform could generate de‑identified real‑world evidence, creating a data moat and new partnership opportunities.

02

Market read

A modest corporate development with limited immediate price impact; primarily a strategic data initiative.

03

What to watch

Potential regulatory scrutiny over health data privacy and the speed of user adoption.

Relevance 4/10Novelty 4/10Timing: today

Background

Glucotrack (NASDAQ:GCTK) operates a diabetes monitoring business and now expands into patient‑reported outcomes via Qare.

Company-level read

Ticker impact

$GCTKNeutralMedium confidence
Context

Glucotrack announced the public launch of Qare, a new health‑data platform for GLP‑1 medications.

Expected impact

limited pressure as market prices in the modest growth opportunity

Evidence & confidence

No financial guidance or sizable contract disclosed; impact depends on user adoption.

Market effects

Adds a digital‑health data player in the diabetes/GLP‑1 space, modestly expanding the health‑tech ecosystem.

U.S. biotech/health‑tech sector may see slight interest, no broader regional effect.

Limited global impact; primarily relevant to investors tracking Glucotrack.

Counterpoint

Without clear monetization metrics, the platform could be a distraction and drain resources.

Key entities

  • Glucotrack, Inc.

    Parent company launching Qare.

  • Lōkahi Therapeutics

    Operates the Qare platform.

Related articles

$GCTKHigh

On July 14, 2026, Glucotrack, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Glucotrack Merger Sub, Inc., a Nevada…

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Other Events. Exhibit 99.1 unaudited pro forma financial information On July 14, 2026 (the “Closing Date”), Glucotrack, Inc., a Delaware corporation (“Glucotrack”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Glucotrack Merger Sub, Inc., a Nevada corporation (“Me

$GCTKMed

GCTK Stock Jumps As Qare Data Platform Launch Fuels Momentum

GlucoTrack Inc. (GCTK) stock surged 14.04% on October 28, 2026, driven by the launch of its Qare data platform. The company's stock has seen significant volatility, trading at $1.95 after a 380% increase from its low. GlucoTrack reported a quarterly net loss of $3.8M and negative free cash flow. The Qare platform, focused on GLP-1 medications, aims to collect and compare patient data, potentially attracting partnerships. The company also expanded its ai² platform globally.

$GCTKMed

Lōkahi plans one shot per visit instead of 15 for honeybee-venom treatment

Lōkahi Therapeutics, a subsidiary of Glucotrack (GCTK), has initiated GMP manufacturing for LT-100, a honeybee-venom-derived biologic for osteoarthritis pain. The company aims to transition from 15 intradermal injections to a single subcutaneous injection per visit. GMP production is a key step in advancing LT-100 through clinical and regulatory milestones, with the first patient enrollment expected later this year, according to the company.

$GLUCMed

Glucotrack Secures $5.5 Million Financing to Support Growth Strategy and Product Development

Glucotrack Inc. said it raised about $5.5 million through institutional financing, including a $2.0 million equity investment priced at $0.75 per unit (share plus 5-year warrant at $1.50) and $3.5 million in follow-on convertible debt. The company plans to use proceeds to fund its implantable continuous blood glucose monitoring program and biopharmaceutical platform via Lōkahi Therapeutics.